Page last updated: 2024-10-25

debrisoquin and Psoriasis

debrisoquin has been researched along with Psoriasis in 2 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chapman, PH2
Rawlins, MD2
Shuster, S2
Idle, JR2
Ritchie, JC1
Smith, RL2
Mahgoub, A1
Mucklow, JC1
Rogers, S1

Other Studies

2 other studies available for debrisoquin and Psoriasis

ArticleYear
Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
    European journal of clinical pharmacology, 1981, Volume: 21, Issue:3

    Topics: Administration, Oral; Adult; Debrisoquin; Heme Oxygenase (Decyclizing); Humans; Hydroxylation; Isoqu

1981
4-Hydroxylation of debrisoquine in psoriasis [proceedings].
    British journal of clinical pharmacology, 1980, Volume: 9, Issue:1

    Topics: Debrisoquin; Humans; Hydroxylation; Isoquinolines; Psoriasis

1980